Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases.

• 影响指数: 3.58
• 发表时间: Mar 2013
• 来源期刊: Rheumatol Int
• DOI: 10.1007/s00296-011-2241-z
• PMID: 22090009
• 文章类型: Case Reports
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Nakagomi D,Ikeda K,Hirotoshi K,Kawashima H,Kobayashi Y,Suto A,Nakajima H

Mesh: Aged; Anti-Inflammatory Agents, Non-Steroidal / adverse effects; Arthritis, Rheumatoid / drug therapy; Cysteine / adverse effects analogs & derivatives; Female; Humans; Male; Yellow Nail Syndrome / chemically induced

Abstract

Yellow nail syndrome is an idiopathic condition characterized by a triad consisting of yellow nail, lymphedema, and pulmonary manifestations. Thiol compounds such as D-penicillamine have been reported to be the major cause of drug-induced yellow nail syndrome in patients with rheumatoid arthritis (RA). We recently experienced two Japanese cases with RA who developed yellow nail under treatment with bucillamine, a thiol-containing anti-rheumatic drug developed and approved in Japan. We reviewed the literature for similar cases and identified 36 RA cases with bucillamine-induced yellow nail, mostly in Japanese medical journals. Most of these cases (90.3%) showed improvement of yellow nail after discontinuation of bucillamine, whereas lymphedema and pulmonary manifestations improved only in 30.8 and 35.0% of the patients, respectively.